Below are the financial statements of CRISPR Therapeutics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | — | — | — |
| Collaboration revenue | 35a | 370a | 0.44a |
| Grant revenue | 2.31a | 1.21a | 0.76a |
| Total revenue | 37.31a | 371.21a | 1.2a |
| Operating expenses | — | — | — |
| Research and development | -320.65a | -387.33a | -461.65a |
| General and administrative | -72.98a | -76.16a | -102.46a |
| Collaboration expense, net | -110.25a | -130.25a | -110.25a |
| Total operating expenses | -503.88a | -593.74a | -674.36a |
| Loss from operations | -466.57a | -222.54a | -673.16a |
| Other income | — | — | — |
| Other income, net | 103.9a | 71.82a | 22.66a |
| Total other income, net | 103.9a | 71.82a | 22.66a |
| Net loss before income taxes | -362.67a | -150.72a | -650.5a |
| (Provision) benefit for income taxes | -3.59a | -2.89a | -0.33a |
| Net loss | -366.25a | -153.61a | -650.18a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore CRISPR Therapeutics’s data sources below and access millions more through our Disclosure Search.